Phase 2 Sjogren's Syndrome Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Rheumatoid Arthritis (RA):
- You have a confirmed diagnosis of rheumatoid arthritis based on recognised medical criteria.
- Your blood tests show a positive result for Rheumatoid Factor (RF) or a related marker called ACPA.
- Your blood tests show signs of inflammation above a certain level (confirm with trial site).
- You have already tried a biological treatment for at least 12 weeks, and your doctor has determined it did not work well enough.
- You currently have at least 6 swollen joints and 6 tender joints.
For people with Sjögren's Disease:
- You have a confirmed diagnosis of primary Sjögren's Disease based on recognised 2016 criteria, confirmed within the last 24 weeks before joining the trial.
- Your disease activity score (called clinESSDAI) is above 6, meaning your condition is considered moderately to severely active (confirm with trial site).
- You still produce a small amount of saliva when tested.
For people with Inflammatory Muscle Disease (IIM):
- Your blood tests show a positive result for certain immune system markers associated with muscle disease.
- Your condition has not responded well enough, or you could not tolerate, at least 3 months of steroid treatment and/or at least one other medication that suppresses the immune system.
- You have had a muscle biopsy or muscle MRI scan confirming your diagnosis within the last 12 months (where applicable).
For people with Systemic Sclerosis (SSc, also known as scleroderma):
- You have a confirmed diagnosis of systemic sclerosis based on recognised 2013 medical criteria.
- Your skin thickening score (called mRSS) is greater than 10, indicating significant skin involvement (confirm with trial site).
- Your diagnosis was first confirmed within the last 8 years.
- Your condition has not responded well enough, or you could not tolerate, at least 3 months of steroid treatment and/or at least one other immune-suppressing medication.
Who may not be able to join:
- No specific exclusion criteria were listed in the information provided — please confirm any restrictions directly with the trial site.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Saddekni, M.D., PgDip, BCMAS, Artiva Therapeutics
Phone: 1 858 223 7001
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.